Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer

NCT05406999 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

900

Enrollment

OTHER

Sponsor class

Conditions

Neoadjuvant Therapy
High Risk Prostate Cancer
Locally Advanced Prostate Cancer
Intense Endocrine Therapy

Interventions

DRUG: ADT
DRUG: Abiraterone Acetate
DRUG: Prednisolone tablets
DRUG: Enzalutamide
DRUG: Apalutamide
DRUG: Darotamide
DRUG: Rezvilutamide
DRUG: PARP inhibitor
PROCEDURE: Robot-assisted radical prostatectomy

Sponsor

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School